Overview of The Human Heredity and Health in Africa Kidney Disease Research Network (H3A-KDRN)

Dwomoa Adu, Akinlolu Ojo and the H3A-KDRN Investigators

Dwomoa Adu
University of Ghana Medical School
University of Ghana
P.O. Box 4236
Accra
Ghana
dwoms15@gmail.com

Akinlolu O. Ojo
University of Kansas School of Medicine
3901 Rainbow Blvd, Mail Stop 1049
Kansas City, KS 66160
aojo@kumc.edu
Introduction:
The increasing prevalence of non-communicable diseases in parallel with a high prevalence of communicable diseases threatens the lives of many in sub-Saharan Africa (SSA) and will overwhelm the already inadequate health budgets of African countries. Chronic kidney disease (CKD) is common in SSA with an estimated average prevalence of 13.9%. Patients with CKD are at increased risk of developing end stage renal disease (ESRD) as well as cardiovascular disease (CVD) and death. The estimated prevalence of ESRD in SSA from diabetes and hypertension is 239 per million population (pmp) and of these only 1.5% of individuals who develop CKD stage 5 have access to maintenance dialysis or kidney transplantation. In a systematic review from Africa, 95% of adults and children with ESRD who could not access dialysis died or were presumed to have died and 84% of adults with new onset ESRD discontinued dialysis. The four to five fold increased risk of ESRD in African Americans as compared to European Americans is now attributed largely to variants in the Apolipoprotein L1 (APOL1) gene in chromosome 22q12 term G1 and G2. Recent studies show that the APOL1 gene variants are also associated with CKD in Africans. The APOL1 gene encodes circulating apolipoprotein L1 which functions as a trypanolytic factor. The APOL1 renal risk variants evolved some 10,000 years ago in SSA where trypanosomiasis was endemic and have risen to a high prevalence in the population because they provided protection against Trypanosoma brucei rhodesiense. These variants are associated with an increased risk of hypertension attributed ESRD, focal segmental glomerulosclerosis, HIV associated nephropathy and other non-diabetic renal diseases. Given that ESRD afflicts an estimated 239,000 (pmp) individuals in SSA annually there is a compelling need for identification of early modifiable risk markers of CKD and a thorough investigation of the genetics of kidney disease causation and progression in African populations to promote the identification of new therapeutic targets and the formulation of effective treatment and prevention strategies.

Methods:
The H3Africa Kidney Disease Research Network (H3A-KDRN) studies the genetic epidemiology and mechanisms of APOL1-associated nephropathy in individuals with CKD using both general populations controls and individuals with hypertension, diabetes, HIV infection, sickle cell disease without CKD. The H3A-KDRN is a research consortium composed of 16 academic medical centers/teaching hospitals in five African countries (Cameroon, Ghana, Nigeria, South Africa and Tanzania (Figure). The H3A-KDRN Principal Investigators met initially by phone conferences but over the last 4 years by web conferences every month. There was active collaboration with 9 North American academic medical institutions and one in Israel. The H3A-KDRN is currently conducting three studies in Africans living in Africa: a) a completed case control study of 4,000 cases of CKD and 4,000 controls that has been described b) an ongoing prospective cohort study of 4000 CKD participants which aims to identify the genetic determinants and characterize the phenotype for kidney disease progression in SSA and c) an ongoing study in two populations with CKD due to childhood onset nephrotic syndrome (NS) and sickle cell anemia (SCA). The prospective cohort study is evaluating the independent contribution of risk variants in the APOL1 genes to the progression of clinically defined nephropathies among 2,500 HIV-negative African Blacks and the effect gene-environment interactions between APOL1 variants and infections (hepatitis B, hepatitis C and polyoma virus) on CKD. It will also evaluate the incidence, histopathological spectrum and the natural history of biopsy-confirmed glomerular diseases in 1,500 HIV-negative African Blacks.

Ethics
The H3A-KDRN together with the H3Africa Consortium has developed a robust ethical framework for genomic research. A key element of this is that potential research participants are given clear information in language that was understood using videos if necessary and that they are given time to consider whether they wish to enroll in the study. The consent process was three pronged with giving information followed by answering questions and finally allowing potential research subjects time typically in excess of a week to decide
whether to consent for the research. A careful explanation was given about broad consent that allows future use of samples and data as this would enable the best use of the research data and samples acquired. All investigators involved in recruitment are required to have mandatory training and certification in human subject protections. All studies received prior IRB/Research Ethics Committee approval. A key part of the ethics approval process has been to engage with national Research Ethics Committees to agree to policies specific to ethical issues attendant to genomic research.\(^9\)

**Training**

We are training clinical investigators and laboratory-based scientists and have developed infrastructure at two sites in Africa to conduct genomic research. Three Africa-based trainees have been trained at the University of Michigan as part of the H3A-KDRN program. A strategy of “mini-sabbaticals” has been implemented with Dr Burke (University of Michigan) visiting H3A-KDRN laboratory groups in the University of Ghana and University of Ibadan, Nigeria. The visits have resulted in the establishment of research laboratories at both sites. Dr Burke has developed a short course of didactic lectures and a guided laboratory procedure, targeted for students in Africa. The laboratory training is linked to an “open-resource” research-quality genetic typing system. Training included: a 2-year training program in clinical research methods and biostatistics with the D43 Fogarty International Center Award (5 investigators); Masters of Science in Human Genetics at the University of Michigan (2 clinical investigators), MPhil in Molecular Biology at the University of Ghana (4 scientists); and NIH BRAD Residency Training Program (2 administrators). Three clinical investigators and four scientists are doing PhDs in clinical epidemiology and human genetics respectively. We also hosted over 11 sessions for training investigators and clinical research coordinators for more than 420 attendees.

**Community engagement**

Our success in recruiting over 12,000 participants for our research studies over the last nine years is largely due to active community engagement. Community engagement is an important component in increasing research participants understanding of genomic research and improving recruitment.\(^10\) The aim has been to increase genomics and clinical research understanding among our key stakeholders that can support the successful implementation of our research projects. We developed community engagement strategies that helped us to engage patients support groups, faith-based institutions, (including Christian and Moslem communities), the kidney patient community and urban communities. We have interviewed H3A-KDRN research participants and their relatives for their views on return of individual genetic findings. The views of genetic research scientists have also been sought as have the views of Ethical Review Committee members in deliberative workshops.

**Biorepositories**

As part of the H3Africa programme three biorepositories were established in Nigeria, Uganda and South Africa for DNA and other biosamples. DNA from the H3A-KDRN has been deposited in the Institute of Human Virology of Nigeria Abuja biorepository.\(^11\) In addition, an H3Africa data and biospecimen access committee was set up to ensure responsible access by scientists from out-with the consortium.

**Results**

Currently 8000 participants have been recruited into the case control study and of these 3000 of these have had a GWAS using the new H3Africa Illumina chip with 2.5 million SNPS enriched for African SNPS. (https://www.h3abionet.org/resources/h3africa-chip). Out of the 3,500 participants enrolled so far into the prospective cohort study, 750 have undergone renal biopsies with light, immunofluorescence, electron microscopy and transcriptional studies in the glomerular and interstitial compartments. A repository of DNA, plasma, serum, urine and kidney tissue provides a rich resource for the study of kidney disease in Africa. Recruitment of participants with HIV CKD, childhood nephrotic syndrome and sickle cell anaemia is ongoing.
Discussion
The lamentable paucity of epidemiologic, genomics and translational studies of kidney disease among Africans represents a major obstacle to preventative and cost-effective interventions by healthcare providers, governments and individual citizens on the African continent. We are now poised to further enhance collaborative efforts in clinical, genomic and translational research across the African continent and these studies will positively impact the understanding of health and disease in Africa. Our training programmes for biomedical scientists, laboratory technicians, research coordinators, grant managers, and administrators within Africa have provided a platform for sustainable research into kidney diseases. The knowledge gained from these studies could have a major impact on kidney disease in both African Blacks and African Americans in the following ways: (1) serve as basis for the development of screening programs for CVD and APOL1-associated nephropathy in high risk populations; (2) generate data for prognostic stratification of CKD and their risk factors; (3) inform public health policy and planning; and (4) identify mechanistic pathways that could ultimately yield new therapeutic targets.

Ancillary Studies
The H3Africa KDRN actively encourages ancillary studies that will complement the aims and objectives of understanding the genomics and clinical aspects of kidney disease in Africa. In particular the framework established would facilitate treatment and prevention studies.

Disclosures
The authors have nothing to disclose.

Funding
Supported by the following grants from NIH/NHGRI/NIDDK H3Africa Kidney Disease Study (U54 HG006939), H3Africa Kidney Disease Cohort Study (U01 DK107131), H3Africa Kidney Disease Collaborative Centers (9U54 DK116913)

Acknowledgments
H3Africa Kidney Disease Research Network

Author Contributions
D Adu: Conceptualization; Methodology; Project administration; Writing - original draft
A Ojo: Conceptualization; Funding acquisition; Methodology; Writing - review and editing
REFERENCES


Figure Legends:

Figure 1: H3A-KDRN Participating Clinical Centers (Academic Medical Centers)

Figure 2: H3A-KDRN Summary Image
## Study Population

<table>
<thead>
<tr>
<th>4000 CKD cases</th>
<th>4000 Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>GWAS in 1500 cases and 1500 controls</td>
<td>2500 HIV negative CKD</td>
</tr>
<tr>
<td>1500 HIV negative biopsy proven glomerulonephritis</td>
<td>600 Childhood nephrotic syndrome</td>
</tr>
<tr>
<td>2200 Sickle cell anaemia</td>
<td>1000 Sickle cell trait</td>
</tr>
</tbody>
</table>

### Investigation of:

- The role of trypanolytic Apolipoprotein L1 (APOL1) gene variants G1 and G2 in predisposition to CKD in Africans in Ghana and Nigeria
- The interaction between APOL1 gene variants and environmental factors such as hepatitis B, C and polyomavirus in progression of CKD and biopsy proven glomerulonephritis in Africans in Ghana and Nigeria
- The role of gene-gene interactions with APOL1 in CKD in Africans in Ghana and Nigeria
- The role of gene variants associated with CKD in patients with sickle cell anaemia
- The association between APOL1 and HLA-DQ1 and steroid response, steroid resistance, frequent relapses and progression to CKD in childhood nephrotic syndrome

### Results

- Over 12,000 subjects recruited
- 750 subjects have had a renal biopsy
- GWAS in 3,000 subjects
- Genotyping for APOL1 variants
- Digital repository of renal biopsies
- Established Community Engagement

### CONCLUSIONS

The knowledge gained from these studies of the genomics and clinico-pathological studies of kidney disease may lead to therapeutic insights.